Max Stock Limited: Immediate report of changes to interested party holdings
Regulations 33(b) of the Securities Regulations (Periodic and Immediate Reports), 1970 CAESAREA, Israel, Dec. 8, 2024 /PRNewswire/ — Max Stock…
Nanning: A Colorful City of Cultural Diversity
BEIJING, Dec. 8, 2024 /PRNewswire/ — A report from China Daily: Nanning, a Chinese city brimming with vitality and historical…
The Best Christmas Gift Ideas for 2024: Transformative Skincare with a Special Holiday Twist
PLEASANTON, Calif., Dec. 8, 2024 /PRNewswire/ — This holiday season, DermRays invites you to redefine the spirit of giving with gifts that…
Monster Energy’s David Wise Claims Third Place in Men’s Freeski Halfipe at the FIS World Cup at China’s Secret Garden
Monster Energy congratulates team rider David Wise on capturing third place in Men’s Freeski Halfpipe at the FIS World Cup…
Riyadh Action Agenda Gathers Steam as Land Governance Takes Center Stage at UNCCD COP16
RIYADH, Saudi Arabia, Dec. 8, 2024 /PRNewswire/ — The role of governance in local, regional and international efforts to tackle…
Riyadh International Philosophy Conference 2024 Concludes with a Focus on Quality of Life
Day 3 explored the philosophical contributions to the quality of life, and the ethical implications of AI and its impact…
University of Nebraska Wins the Abbott and Big Ten Conference’s Nationwide ‘We Give Blood Drive’ Competition, Receives $1 Million Grant from Abbott
Nearly 20,000 Big Ten students, alumni and fans across the country donated blood as part of the Abbott-Big Ten nationwide…
Preclinical Study Shows Targeted Drug Strengthens the Power of CAR T-Cell Therapy in Two Pediatric Leukemias
A preclinical study led by a faculty member at Roswell Park shows that gilteritinib (brand name Xospata), a targeted cancer…
Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Shows High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
Data presented at the 66th Annual Meeting and Exposition of the American Society of Hematology (ASH) NORTH CHICAGO, Ill., Dec.…
Syndax Presents Positive Revuforj® (revumenib) Data in Acute Leukemias from Multiple Trials, Including the SAVE Combination and AUGMENT-101 Trials, at 66th ASH Annual Meeting
– 82% ORR (27 of 33 pts) and 48% CR/CRh (16 of 33 pts) in SAVE trial studying revumenib in…
New Data from PROMMIS Study Highlights the Power of SKY92 in Identifying High-Risk Multiple Myeloma Patients
ROTTERDAM, the Netherlands and SAN DIEGO, Dec. 7, 2024 /PRNewswire/ — SkylineDx, an innovative diagnostics company specializing in the research…
MosquitoMate receives first Vector Expedited Review Voucher (VERV) from the US Environmental Protection Agency
LEXINGTON, Ky., Dec. 7, 2024 /PRNewswire/ — The US Environmental Protection Agency (EPA) has just announced MosquitoMate as its first…
Building Homes for Heroes Gifts 400th Home, Marking Historic Achievement in Veteran and First Responder Support
Building Homes for Heroes & Hillwood Properties partner to gift milestone home in Dallas, Texas NEW YORK, Dec. 7, 2024…
OpsHub Amplifies its Presence on the Visual Studio (VSTS) Marketplace
OpsHub has expanded its presence on Visual Studio (VSTS) marketplace with new Azure DevOps integrations with leading tools like Jira,…
Updated Results of Phase 3 ALLELE Study Presented at 66th American Society of Hematology Annual Meeting Confirm Efficacy, Safety and Durability of Novel Allogeneic Cell Therapy Tabelecleucel in Relapsed or Refractory Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD)
Tabelecleucel treated relapsed or refractory EBV+ PTLD patients achieved a 50.7% Objective Response Rate (ORR), 23.0-month Median Duration of Response (DOR), and Median Overall Survival (OS)…
↑